Moderate versus high-titer persistently anticardiolipin antibody positive patients: Are they clinically different and does high-titer anti-β2-glycoprotein-I antibody positivity offer additional predictive information?

Abstract

The association between antiphospholipid antibodies (aPL) and clinical events is stronger with a positive lupus anticoagulant (LA) test, higher anticardiolipin antibody (aCL) titers, and/or higher anti-β₂-glycoprotein-I antibody (aβ₂GPI) titers. The objective of this study was to determine the clinical characteristics of persistently high-titer (≥80 U) aCL-positive patients compared with those with persistent moderate aCL titers (40—79 U). Second, we analyzed whether high-titer aβ₂GPI test adds predictive information in persistently moderate-to-high titer aCL-positive patients. In this cross-sectional study, the primary analysis compared the clinical and aPL characteristics of 58 patients with at least two moderate-titer aCL results to another 85 patients with at least two high-titer aCL results. In the secondary analysis of patients with at least two aβ₂GPI test results, we compared 29 patients with ‘aCL 40—79 U and aβ₂GPI < 80 U’ profiles with 8 patients with ‘aCL 40—79U and aβ₂GPI ≥ 80 U’, and also compared 27 patients with ‘aCL > 80 U and aβ₂GPI < 80 U’ with 32 patients with ‘aCL > 80 U and aβ₂GPI ≥ 80 U’. Although aPL-related vascular and pregnancy events were similar between the moderate- and high-titer aCL groups, the number of patients with positive LA tests (RR 2.06, CI 1.38—3.08, p < 0.01) and with at least one non-criteria aPL manifestation (RR 1.66, CI 1.20—2.30, p = 0.0005) were significantly higher in the high-titer aCL group. While magnetic resonance imaging (MRI) white matter changes were statistically more common in the high-titer aCL group (RR 2.03, CI 1.04—3.94, p = 0.02), there was a trend towards increased prevalence of livedo reticularis, cardiac valve disease, and cognitive dysfunction occurring in the high-titer aCL group. The secondary analysis showed that MRI white matter changes, cardiac valve disease, and cognitive dysfunction were proportionally more common in the high-titer aβ₂GPI groups, suggesting a linear relationship between non-criteria aPL manifestations and aPL titers. Our results suggest that patients with high aCL titers, compared with those with moderate titers, are more likely to have a positive LA test and a higher prevalence of non-criteria aPL manifestations. Furthermore, high-titer aβ₂GPI positivity may further increase the prevalence of non-criteria aPL manifestations in moderate- or high-titer aCL-positive patients.

Keywords

anti-β2-glycoprotein-I antibodies anticardiolipin antibodies antiphospholipid antibodies antiphospholipid syndrome

Get full access to this article

View all access options for this article.

References

Miyakis S. , Lockshin MD , Atsumi T. , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006; 4: 295-306.

Galli M. , Reber G. , De Moerloose P. , De Groot PG Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008; 6: 399-401.

Galli M. , Luciani D. , Bertolini G. , Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature . Blood 2003; 101: 1827-1832.

Varley M. , Varley L. , Erkan D. , et al. Lupus anticoagulant positivity is associated with higher titers of anticardiolipin and anti-β2-glycoprotein-I antibodies. Arthritis Rheum 2005; 52: 4103 (abstract).

Galli M. , Borrelli G. , Jacobsen EM , et al. Clinical Significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 2007; 110: 1178-1183.

Levine SR , Salowich-Palm L. , Sawaya KL , et al. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study . Stroke 1997; 28: 1660-1665.

Lockshin MD , Druzin ML , Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol 1989; 160: 439-443.

Galli M.

Antiphospholipid antibodies and thrombosis: do test patterns identify the patients’ risk?

Thromb Res 2004; 114: 597-601.

Rufatti A. , Del Ross T. , Ciprian M. , et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: A multicentre, retrospective follow-up study. Ann Rheum Dis 2009; 68: 397-399.

10.

Erkan D. , Derksen WJ , Kaplan V. , et al. Real world experience with antiphospholipid antibody tests: how stable are results over time? Ann Rheum Dis 2005; 64: 1321-1325.

11.

Lee EY , Lee CK , Lee TH , et al. Does the anti-beta2-glycoprotein I antibody provide additional information in patients with thrombosis? Thromb Res 2003; 111: 29-32.

12.

Kaplan V. , Erkan D. , Sammaritano L. , Pierangeli SS , Roubey R. , Lockshin MD Real world experience with antiphospholipid antibodies: the significance of double versus triple aPL positivity. Arthritis Rheum 2005; 52: S593-S594 (abstract).

13.

Chapman J. , Cohen-Armon M. , Shoenfeld Y. , Korczyn AD Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes . Lupus 1999; 8: 127-133.

14.

Kozora E. , Hanly JG , Lapteva L. , Filley CM Cognitive dysfunction in systemic lupus erythematosus: past, present, and future. Arthritis Rheum 2008; 58: 3286-3298.

15.

Kozora E. , Archiniegas DB , Filley CM , et al. Cognitive and neurologic status in patients with systemic lupus erythematosus without major neuropsychiatric syndromes. Arthritis Rheum 2008; 59: 1639-1646.

16.

Tenedios F. , Erkan D. , Lockshin MD Cardiac involvement in the antiphospholipid syndrome. Lupus 2005; 14: 691-696.